Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PDE8B | O95263 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337349 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2PDE8BALDH1A1NPC1 | |
| SCHEMBL337037 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2PDE8BALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL1026857 | 0.98 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2PDE8BALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL1027414 | 0.98 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2PDE8BALDH1A1NPC1 | |
| SCHEMBL344947 | 0.95 | PDE8B (0.49) | HSD17B10SMN1; SMN2PDE8BALDH1A1ATM | |
| SCHEMBL80021 | 0.95 | PDE8B (0.49) | HSD17B10SMN1; SMN2PDE8BALDH1A1ATM | |
| SCHEMBL283705 | 0.95 | PDE8B (0.49) | HSD17B10SMN1; SMN2PDE8BALDH1A1ATM | |
| SCHEMBL20214777 | 0.94 | PDE8B (0.48) | HSD17B10SMN1; SMN2PDE8BALDH1A1ATM | |
| SCHEMBL20186804 | 0.94 | PDE8B (0.48) | HSD17B10SMN1; SMN2PDE8BALDH1A1ATM | |
| Hydrochloric Acid SCHEMBL3564519 | 0.94 | PDE8B (0.48) | HSD17B10SMN1; SMN2PDE8BALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036730-A | Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof | 中山大学 | 2026-05-15 | — | — | CN | claimed |
| CN-119875045-A | Pyrenyl covalent organic framework material and preparation method and application thereof | 中国石油天然气股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-118344278-A | Rosin amino acid compound and preparation method and application thereof | 广西中医药大学 | 2024-07-16 | — | — | CN | claimed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | claimed |
| CN-122036730-A | Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof | 中山大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HAGER BIOSCIENCES, LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4700021-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Sapiensbio Inc. (KR) | 2026-02-25 | — | — | EP | disclosed |
| WO-2025242908-A2 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4644380-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-5736549-A | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE, USED FOR TREATING OR PREVENTING TISSUE REJECTION OR SELECTIVE SUPPRESSION OF MAMMALIAN T-CELL FUNCTION | CHIROSCIENCE LIMITED (GB) | 1998-04-07 | — | — | US | disclosed |
| EP-0784624-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996011200-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0539281-A1 | New naphthamides, process for their preparation and their application in the therapeutical field | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-04-28 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | HSD17B10 1400/4885SMN1; SMN2 2243/4885PDE8B 3335/4885 |
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | OPRK1, OPRD1, HCRTR2 | HSD17B10 3121/4885SMN1; SMN2 2034/4885PDE8B 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.